The aim of our study was to monitor the dynamics of the serological response to different application routes of live attenuated myxomatosis vaccine. The study included 42 Californian breed rabbits, aged 3 mo, of both sexes. They were separated into 7 groups: 6 experimental and 1 control. All experimental groups were vaccinated on day 0 with a single dose of myxomatosis vaccine (min 10^3.3 tissue culture infective dose 50 [TCID₅₀], max 10^5.8 TCID₅₀). Three of the groups were injected with monovalent attenuated myxomatosis vaccine using different types of application: intradermal (i.d.), intramuscular (i.m.) and subcutaneous (s.c.). The other 3 groups were injected with bivalent attenuated vaccine against myxomatosis and rabbit haemorrhagic disease; again the routes of administration were i.d., i.m. and s.c.. There were no clinical signs or serious side effects after vaccination. The serological response was evaluated on days 7, 15 and 30 with a monoclonal antibody based-competition enzyme-linked immunosorbent assay (cELISA). More rapid and potent humoral response was detected in groups with i.d. inoculation in comparison to i.m. and s.c. routes. Vaccination with monovalent vaccine against myxomatosis induced higher antibody titre in comparison to bivalent vaccine. Our study showed that the vaccine application route and the type of vaccine used influence the speed and intensity of antibody response.

In the pig farm with signs of a respiratory disease complex and laboratory confirmed enzootic pneumonia, the prophylactic efficacy of the combination vaccine (M. hyo+PCV2), a single injection administered intramuscularly 21 days after birth, at a dose of 2 ml was tested. The clinical condition, pathological changes in the lungs and some epidemiological and economic results were reported. It was found that vaccinated pigs are in a better clinical condition in comparison with the control group. Morbidity in the rearing period was reduced from 16.3% in the control group to 6.0% in vaccinated pigs, and in the fattening period, respectively, from 30.6% in the control group to 10.0% in the vaccinated group. Pathological features in the lung characteristic for the enzootic pneumonia in the vaccinated pigs were reduced from 25.5%±7.24 to 4.0%±2.44, and PCVIfrom 13.0%±4.66 to 0%. Vaccination of pigs has been received and a higher average daily gain in groups for rearing (0.624 kg) and for fattening (0.723 kg) was recorded.

No abstract

Actinobacillus pleuropneumoniae (App) is the etiological agent of porcine pleuropneumonia. The purpose of the study was to present a serological report on App prevalence among pigs in industrial farms in Bulgaria. Seventy-two pigs from four industrial farms in four districts of Bulgaria – Eastern Bulgaria (Razgrad and Yambol districts) and Western Bulgaria (Lovech and Sofia districts) were included. Animals were divided in two age groups: weaners and fattening pigs. A commercial enzyme-linked immunosorbent assay (ELISA, INgezim APP MIX, Eurofins Ingenasa, Madrid, Spain) for the detection of antibodies against App parasuis in porcine serum was used. Microtitrе plate was coated with App antigen of the serovars 1, 2, 9 and 11. Positive results for anti-App antibodies were detected in 32 (44.4%) of all 72 tested sera. The overall seropositivity in weaners and fattening pigs was 22.2% (8/36), and 66.7% (24/36), respectively. The highest App seropositivity in pigs was found in Eastern Bulgaria - 61.1% (22/36; P<0.001) in comparison to App seropositivity in Western Bulgaria – 27.8% (10/36; P=0.137). This study on anti-App prevalence among pigs in Bulgaria gives new insights on App epidemiology in our country.